| Effect | None |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 30 |
| Gender | Both Genders |
| Age Range | 7-12, 13-17, 18-29, 30-44 |
DSM 17938 at 10^8^ CFU daily for six months noted that, in a double blind crossover design, that persons with cystic firbosis experienced a betterment of intestinal discomfort associated with beneficial changes in the gut microflora (which is inherently altered from the norm in cystic fibrosis). Despite benefits to intestinal discomfort, no overall changes were noted on the SF-12 (general health survey).
Lung power and inflammatory/antiinflammatory cytokines were all unaffected, although fecal calprotectin (biomarker of intestinal inflammation) was reduced by 40%.
